Filing Details

Accession Number:
0001104659-20-080019
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-07-01 21:15:07
Reporting Period:
2020-06-29
Accepted Time:
2020-07-01 21:15:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1235010 Momenta Pharmaceuticals Inc MNTA Biological Products, (No Disgnostic Substances) (2836) 043561634
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1798748 Agnieszka Cieplinska C/O Momenta Pharmaceuticals, Inc.
301 Binney Street
Cambridge MA 02142
Chief Accounting Officer (Pao) No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-06-29 3,150 $0.00 8,521 No 4 A Direct
Common Stock Disposition 2020-06-30 947 $35.11 7,574 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Acquisiton 2020-06-29 3,150 $0.00 3,150 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
9,450 No 4 A Direct
Footnotes
  1. Shares received pursuant to settlement of Performance Stock Units that were granted on April 12,2019.
  2. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  3. Each Restricted Stock Unit represents a contingent right to receive one share of MNTA common stock.
  4. Subject to the officer's continued employment with the company, 3,150 Restricted Stock Units will vest on June 29, 2021.